ClinicalTrials.gg
CompletedNCT00706693Updated Jul 9, 2008

Skittles(TM) Effective for Treating Hypoglycemia in Children With Type 1 Diabetes

An interventional study of Ingestion of BD glucose tablets (TM) and Ingestion of Skittles (TM) in Type 1 Diabetes Mellitus and Hypoglycemia, sponsored by University of Calgary. Completed at 1 site in Canada. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2008-07-09.

Sponsored by University of Calgary · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Study summary

The purpose of this study is to determine the most effective treatment option for managing naturally occurring hypoglycemia in children with type 1 diabetes.

Hypotheses:

  1. Sucrose and Fructose are equally effective as glucose in the treatment of spontaneous hypoglycemia in children with type 1 diabetes.
  2. Children and teens will use a variety of treatment practices for the management of hypoglycemia.
  3. Children and teens will prefer the mode of treatment that was most effective in treating hypoglycemia.
Read the detailed description

An open labeled, randomized, cross-over design will be used. Each subject will treat 5 hypoglycemic events with glucose, 5 with sucrose and 5 with fructose. Subjects will be randomized into order of treatment.

Primary Objective:

  1. To determine if sucrose and fructose are equally effective as glucose in the treatment of spontaneous hypoglycemia in children with type 1 diabetes.

    Secondary Objectives:

  2. To determine present hypoglycemia treatment practices of children and teens with type 1 diabetes (prior to entry into the study).
  3. To determine preferred mode of treatment for hypoglycemia after completing the study.

Inclusion Criteria:

The sample will consist of 65 individuals with a history of type 1 diabetes (based on clinical presentation) for three or more months and who are between the ages of 3 and 18 years. All eligible participants will be patients of the Alberta Children's Hospital Diabetes Clinic.

Exclusion Criteria:

Individuals with the following conditions/circumstances will be excluded from the study:

  • adrenal insufficiency
  • uncompensated hypothyroidism
  • clinical autonomic neuropathy
  • celiac disease
  • lack of family support
  • unwilling or unable to follow the study protocol
  • subjects with less than 4 hypoglycemic events per month

Instruments:

Blood glucose will be measured with a blood glucose meter. All meters will have a lab to meter comparison performed. In accordance with the 1998 Clinical Practice Guidelines for Diabetes Management in Canada, an acceptable meter value will be +15% of the lab value (7). Participants will be provided with a complimentary meter and strips.

All participants will be provided with a digital timer to enable accurate 15 minute timing of post treatment blood glucose.

A Demographic and Pre-Study Data tool has been developed to collect pre-study information (see Appendix B) as well as a Low Blood Glucose Treatment Log to record pre- and post-treatment blood glucose results (see Appendix C).

Study Procedure:

A letter inviting participation in the study will be mailed to all eligible participants (see Appendix D). Further recruitment will be done during clinic appointments. Six months will be allocated for recruitment of subjects. Subjects will meet with the study research assistant and informed and signed consent will be obtained. Participants will be assigned a study number based on their order of recruitment. The research assistant and participant will not determine treatment order. Each participant will be assigned a treatment order based on a randomization table (See Table 1).

The research assistant will also obtain demographic data and information on present hypoglycemia treatment practices, explain the study protocol, and provide Study Protocol instructions (see Appendix E). The lab/meter comparison will be obtained prior to data collection.

The study protocol is as follows:

  • Hypoglycemia will be confirmed with a blood glucose test.
  • If blood glucose is less than 4.0 mmol/L it will be treated with pre-packaged treatments and in the order determined by randomization.
  • The blood glucose will be re-tested 15 minutes after treatment.
  • If the blood glucose is still less than 4.0 mmol/L, it will be treated again as per study protocol and then re-tested 15 minutes later.
  • If the next meal or snack is more than 1 hour away, a snack containing 15 g of carbohydrate and a protein will be eaten.
  • Participants will record blood glucose results and treatment method on the Low Blood Glucose Treatment Log.

If participants can not follow the above outlined protocol, they will be instructed to treat as per usual practice and not record data. This will mean that most hypoglycemic events treated as per protocol will likely occur when children are with their parents or in the comfort of their own homes.

Assuming that children and teens will experience 1 to 3 hypoglycemic events per week, it is anticipated that data collection will occur over a 5 to 15 week period. The research assistant will call participants every two weeks to monitor study progress. Once the subject has treated 15 hypoglycemic episodes as per study protocol and completed the Low Blood Glucose Treatment Log, they will return it in a pre-addressed and stamped envelope. There will be a question at the end of the Low Blood Glucose Treatment Log asking preferred method of hypoglycemia treatment following completion of the study.

02

Conditions studied

  • Type 1 Diabetes Mellitus
  • Hypoglycemia

Keywords

  • hypoglycemia
  • treatment
  • glucose
  • sucrose
  • fructose
03

In context

Diabetes Mellitus, Type 1

3,614 studies on the registry are indexed under Diabetes Mellitus, Type 1; 586 are open to participants now.

This study's enrollment of 33 is below the median of 40 across 2,718 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

University of Calgary is the lead sponsor of 699 studies on the registry; 192 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes mellitus
  • Diagnosed 6 or more months ago
  • Patient of the Alberta Children's Hospital Diabetes Clinic

Exclusion criteria

Exclusion Criteria:

  • Adrenal insufficiency
  • Uncompensated hypothyroidism
  • Clinical autonomic neuropathy
  • Celiac disease
  • Lack of family support
  • Unwilling or unable to follow the study protocol
  • Subjects with less than 4 hypoglycemic events per month
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Active comparator
    Glucose

    BD glucose tablets (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm

    Dietary Supplement: Ingestion of BD glucose tablets (TM)

  • Active comparator
    Fructose

    Fruit to Go (TM) is taken PO in response to a hypoglycemic event by participants randomized to this arm

    Dietary Supplement: Ingestion of Fruit to Go (TM)

  • Active comparator
    Sucrose

    Skittles (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm

    Dietary Supplement: Ingestion of Skittles (TM)

Interventions

  • Dietary supplementIngestion of BD glucose tablets (TM)

    Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.

  • Dietary supplementIngestion of Skittles (TM)

    Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.

  • Dietary supplementIngestion of Fruit to Go (TM)

    Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.

06

What researchers measure

Primary outcomes

  1. To determine if sucrose and fructose are equally effective as glucose in the treatment of spontaneous hypoglycemia in children with type 1 diabetes.

    Time frame: 15 minutes

Secondary outcomes

  1. To determine present hypoglycemia treatment practices of children and teens with type 1 diabetes (prior to entry into the study).

  2. To determine preferred mode of treatment for hypoglycemia after completing the study.

07

Study locations

1 site
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
08

References and documents

Publications

  • Husband AC, Crawford S, McCoy LA, Pacaud D. The effectiveness of glucose, sucrose, and fructose in treating hypoglycemia in children with type 1 diabetes. Pediatr Diabetes. 2010 May;11(3):154-8. doi: 10.1111/j.1399-5448.2009.00558.x. Epub 2009 Aug 3. PubMed 19663922 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00706693
Collaborators
Canadian Diabetes Association, LifeScan Canada, Becton, Dickinson and Company
First posted
Jun 27, 2008
Start date
Aug 2003
Primary completion
Sep 2006
Completion
Sep 2006
Last update
Jul 9, 2008

Study contacts

Allison Husband, RN, MN, CDE
principal investigator · Alberta Children's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion